GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2008

ZaBeCor Forms Subsidiary that Will Concentrate on siRNA Cancer Therapies

  • ZaBeCor Pharmaceuticals has formed a subsidiary, Biothorpe Pharmaceuticals, to focus on the development of siRNA, antisense, and other molecular technologies for cancer treatment. Biothorpe's intellectual property (IP) portfolio includes the therapeutic use of siRNA and other oligonucleotides directed at Syk kinase, which is required for the proliferation of malignant cells in several cancers, according to some studies.

    The company intends to license its IP for the treatment of three cancers: acute myelogenous leukemia, B-cell lymphoma, and chronic lymphocytic leukemia. Biothorpe's IP is based upon research conducted at the University of Pennsylvania School of Medicine.

    “ZaBeCor will continue to focus on inflammatory disorders, particularly on developing our anti-inflammatory drug candidate Excellair™, while Biothorpe builds upon the groundbreaking research of applying siRNA technology toward malignant cells in the blood and lymphatic system.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

New NIH Budget Proposal Leaves Many Confused and Unsettled

Do you think that using the so-called “mandatory budget funds” to pay for the proposed $825 million increase, as well as $1 billion of the NIH’s existing budget is a good idea?

More »